Detalhe da pesquisa
1.
Integrated mutational landscape analysis of uterine leiomyosarcomas.
Proc Natl Acad Sci U S A
; 118(15)2021 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876771
2.
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Cancer
; 128(6): 1206-1218, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34875107
3.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Proc Natl Acad Sci U S A
; 116(2): 619-624, 2019 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30584090
4.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Proc Natl Acad Sci U S A
; 116(45): 22730-22736, 2019 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31624127
5.
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Gynecol Oncol
; 163(2): 334-341, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452746
6.
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
Gynecol Oncol
; 158(3): 769-775, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32600791
7.
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Gynecol Oncol
; 156(2): 430-438, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31839338
8.
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Gynecol Oncol
; 155(1): 144-150, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31434613
9.
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Gynecol Oncol
; 153(1): 158-164, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30630630
10.
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Proc Natl Acad Sci U S A
; 113(43): 12238-12243, 2016 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27791010
11.
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Gynecol Oncol
; 149(3): 585-591, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29572027
12.
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
Gynecol Oncol
; 146(1): 179-186, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28473206
13.
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
Gynecol Oncol
; 147(1): 145-152, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28705408
14.
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Gynecol Oncol
; 144(1): 146-152, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27894751
15.
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Br J Cancer
; 115(3): 303-11, 2016 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27351214
16.
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Am J Obstet Gynecol
; 214(1): 99.e1-8, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272866
17.
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.
Int J Cancer
; 137(11): 2618-29, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26060989
18.
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
Cancer
; 121(3): 403-12, 2015 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25251053
19.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br J Cancer
; 113(7): 1020-6, 2015 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26325104
20.
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Tumour Biol
; 36(7): 5505-13, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25669172